India has billion plus population and a home for various life threatening diseases. These factors provide an opportunity for global medical practitioners and healthcare providers to consider India as an effective destination for research and clinical studies. India has registered fast growth in the number of clinical trials over the past few years, reflecting that the country has become one of the most attractive destinations for medical research.
According to our new research report, "Booming Clinical Trials Market in India", the number of clinical studies by domestic and global players has sharply risen. The M&A activities, service agreements, and strategic collaboration have increased over the last four years. The majority of the deals in the contract research organizations market focused on establishing strategic alliances with other contract research organizations, technology providers, and pharmaceutical and biotech companies. In addition, on the back of favorable government support and effective regulatory mechanism provided by the ICMR and CDSCO, healthcare providers find it worthwhile to locate their trials in India. Besides, availability of skilled manpower and good medical infrastructure will augment the number of clinical trials from 1300 in 2009 to more than 1900 by 2013.
We have analyzed the Indian clinical trial market with emphasis on current market trends and future outlook. Our report has found that with the rising participation of private players and improvement in the number of medical professionals, new avenues of research will be developed in the country. All these factors will facilitate market development and boost market growth in future. A large number of patients for clinical trials are expected to strengthen the market even more.
Our study indicates that, India, over the last decade, has developed significant capabilities in clinical trials, along with certain capabilities in project management and data management. India is able to provide significant cost savings of 50-60% for clinical trials. With discovery research occupying close to one-third of the R&D expenditure for the western pharmaceutical industry, outsourcing to low-cost countries is logical. As the financial and regulatory pressure grows on the US and European pharmaceutical industry, it is expected to further propel the growth in the Indian clinical trial market.
Our report is an outcome of extensive research and prudent analysis of the Indian clinical trial market. The report covers all the necessary segments of the sector, providing reliable and latest data of the industry. The report also presents future outlook of different areas. Moreover, the description of key players and their recent activities have been covered in the report.
1. Analyst View
2. Research Methodology
3. Clinical Trials Market Overview
3.1 Clinical Trials Market
3.2 Clinical Trials by Type
3.3 Number of Clinical Trials
3.4 State-wise Trials
4. Growth Facilitators and Emerging Trends
4.1 Cost Competitiveness in Conducting Clinical Trials
4.2 Faster Completion of Clinical Trials
4.3 Government Support
4.4 Clinical Data Management: Demand of the Hour
4.5 Pharma Outsourcing Market
4.6 Pathology and Diagnostic Market
5. Size and Patient Pool Availability
5.1 Demographics Profile
5.2 Disease Profile
5.3 Patient Availability and Recruitment
6. Infrastructure and Expertise
7. Business Outsourcing Models Followed by Players
8. Procedure for Conducting Clinical Trials
9. Regulatory Environment
10. Industry Bottlenecks and Precautions
11. Cost Analysis for Clinical Trials
11.1 Total Budget Cost
11.2 Cost Comparison with US
11.3 Cost Analysis by Phases
11.3.1 Phase I (Cost of Utility and Staff)
11.3.2 Phase II (Cost of Utility and Staff)
11.3.3 Phase III (Cost of Utility and Staff)
11.3.4 Phase IV (Cost of Utility and Staff)
12. Competitive Landscape
12.1 Overview
12.2 Competitive Landscape
12.2.1 Veeda Clinical Research
12.2.2 SIRO Clinpharm Private Limited
12.2.3 Sipra Labs Limited
12.2.4 Clintrac International
12.2.5 Clinigene International
12.2.6 Quintiles India
12.2.7 Synchron Research Services
12.2.8 Max Neeman International
12.2.9 DiagnoSearch Life Sciences
12.2.10 Vimta Labs
12.2.11 Lambda Therapeutic Research
12.2.12 Ecron Acunova
List of Figures:
Figure 3-1: Clinical Research Outsourcing Market (Million
US$), 2009-2015
Figure 3-2: Clinical Trials by Phase (%)
Figure 3-3: Clinical Trials by Therapy (%)
Figure 3-4: Clinical Trials by Funding (%)
Figure 3-5: Number of Global and Local Trials Permitted
(2007-2010)
Figure 3-6: Number of Clinical Trials (2007 & 2009)
Figure 4-1: Average Annual Cost for Conducting Clinical
Trials in Comparison to US
Figure 4-2: Investigator Cost per Visit in Comparison to
US, UK and Singapore
Figure 4-3: Numbers of Clinical Trials Completed on Time
in Comparison to UK, US and Germany
Figure 4-4: Time Taken for Conducting Clinical Trials by
Phase in Comparison to US (Months)
Figure 4-5: Pharma Outsourcing Market (Billion US$), 2009
-2013
Figure 4-6: Pharma Outsourcing Market by Segment (%),
2008
Figure 4-7: IVD Market (Million US$), 2009 & 2012
Figure 5-1: Population (Million), 2009-2013
Figure 5-2: Population Breakup by Age Group (%), 2009
-2013
Figure 5-3: New and Total Number of Cancer Patients
(’000)
Figure 5-4: Number of Hypertension Patients (Million), 2009
& 2025
Figure 5-5: Number of Coronary Heart Disease Patients
(Million), 2010 & 2015
Figure 5-6: Recruitment Time for Patients Participating in
Clinical Trials in Comparison to US (Days)
Figure 5-7: Number of Patient per Site in Comparison to
US
Figure 6-1: Annual Supply of Science Graduates and
Postgraduates (’000)
Figure 6-2: Number of Graduates and Postgraduates
(Million), 2004
Figure 6-3: Share of Science Doctorates in Total
Doctorates (2004)
Figure 6-4: Number of Doctors in Comparison to US and
Germany (per ’000 Population), 2009
Figure 6-5: Demand-Supply Gap in Clinical Research
Professionals (Number), 2010
Figure 6-6: Number of GCP Trained Investigators (2002 &
2005)
Figure 6-7: Number of GCP Trained Investigators in
Comparison to US
Figure 6-8: Number of Hospital Beds (’000), 2009-2013
Figure 6-9: Hospital Beds Density of Key Countries (per
’000 Population), 2010
Figure 6-10: Number of Industry Sponsored Phase II-III
Clinical Trial Sites of Key Countries
Figure 11-1: Average Cost per Patient for Conducting
Clinical Trials in Comparison to UK, US and Germany (US
$)
Figure 11-2: Average Cost per Patient for Conducting
Phase I Clinical Trials in Comparison to UK, US and
Germany (US$)
Figure 11-3: Average Cost per Patient for Conducting
Phase II Clinical Trials in Comparison to UK, US and
Germany (US$)
Figure 11-4: Annual Cost of Office Space for Conducting
Phase II Clinical Trials in Comparison to UK, US and
Germany (US$)
Figure 11-5: Average Cost per Patient for Conducting
Phase III Clinical Trials in Comparison to UK, US and
Germany (US$)
Figure 11-6: Annual Cost of Office Space for Conducting
Phase III Clinical Trials in Comparison to UK, US and
Germany (US$)
Figure 11-7: Average Cost per Patient for Conducting
Phase IV Clinical Trials in Comparison to UK, US and
Germany (US$)
Figure 11-8: Annual Cost of Office Space for Conducting
Phase IV Clinical Trials in Comparison to UK, US and
Germany (US$)
List of Tables:
Table 3-1: Details of State-wise Clinical Trials (January-
July 2011)
Table 4-1: Features of Clinical Trials in Comparison to US
Table 5-1: Number of Deaths due to Leading Causes in
Middle Income Countries (Million)
Table 5-2: Number of Diabetic Patients in Age Group 20-79
(’000), 2010
Table 5-3: Forecast for Number of Diabetic Patients in Age
Group 20-79 (’000), 2030
Table 5-4: New Cancers Incidences (per ’00,000 Females),
2005
Table 5-5: New Cancers Incidences (per ’00,000 Males),
2005
Table 5-6: Obesity Statistics (2009)
Table 6-1: Structure of Medical Education
Table 6-2: Number of GLA Approved Facilities by Type
Table 9-1: Regulatory Bodies Involved in Pharmaceutical
Regulation
Table 9-2: Regulatory Timelines for Conducting Clinical
Trials
Table 11-1: Average Cost of Clinical Research in
Comparison to US by Phase (Million US$)
Table 11-2: Calculation of Clinical Trials Costs Savings in
Comparison to US
Table 11-3: Annual Cost of Staff for Conducting Phase I
Clinical Trials in Comparison to UK, US and Germany (US
$)
Table 11-4: Annual Cost of Utility for Conducting Phase I
Clinical Trials in Comparison to UK, US and Germany (US
$)
Table 11-5: Annual Cost of Staff for Conducting Phase II
Clinical Trials in Comparison to UK, US and Germany (US
$)
Table 11-6: Annual Cost of Utility for Conducting Phase II
Clinical Trials in Comparison to UK, US and Germany (US
$)
Table 11-7: Annual Cost of Staff for Conducting Phase III
Clinical Trials in Comparison to UK, US and Germany (US
$)
Table 11-8: Annual Cost of Utility for Conducting Phase III
Clinical Trials in Comparison to UK, US and Germany (US
$)
Table 11-9: Annual Cost of Staff for Conducting Phase IV
Clinical Trials in Comparison to UK, US and Germany (US
$)
Table 11-10: Annual Cost of Utility for Conducting Phase
IV Clinical Trials in Comparison to UK, US and Germany
(US$)
Other selected research from the 'Business Development' category:
Partneringdesk Altana AG and Company Deals Briefing
Global Anti-Obesity Treatments Market 2010-2025
Other selected research from the 'India' category:
Clinical Diagnostics in India: Market Analyses and Participant Directory
Opportunities in Indian Healthcare Sector
Other selected research from the 'Markets' category:
Partneringreview 2006 - Therapy area (volume 2)
OTC Pharmaceuticals in Asia-Pacific